| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(4 years from now) | |
| US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(5 years from now) | |
| US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(7 years from now) | |
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(13 years from now) | |
Pylarify is owned by Progenics Pharms Inc.
Pylarify contains Piflufolastat F-18.
Pylarify has a total of 4 drug patents out of which 0 drug patents have expired.
Pylarify was authorised for market use on 26 May, 2021.
Pylarify is available in solution;intravenous dosage forms.
Pylarify can be used as method of positron emission tomography (pet) in men with prostate cancer.
Drug patent challenges can be filed against Pylarify from 2025-05-26.
The generics of Pylarify are possible to be released after 09 June, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 2025-05-26
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION;INTRAVENOUS
PYLARIFY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic